Immuno-Oncology | Specialty

Finding the Best Spot for PD-1/PD-L1 Antibodies in Advanced Lung Cancer

January 11th 2018

Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.

McDermott Shares Insight on Immunotherapy in RCC

January 10th 2018

David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.

FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC

January 9th 2018

The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.

Adjuvant Pembrolizumab Improves RFS in Melanoma

January 9th 2018

Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.

Practical Questions on Checkpoint Agents Arise

January 5th 2018

Despite the promising developments in this arena, many patients with cancer respond inadequately to immune checkpoint monotherapy, and others develop serious (grade 3-4) toxicities that require treatment cessation.

Japan Approves Pembrolizumab for Urothelial Carcinoma

January 3rd 2018

The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy

Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

January 3rd 2018

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Reckamp Recounts Recent Lung Cancer Advances

January 2nd 2018

Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).

Various Immunotherapy Combinations Continue to Be Explored in NSCLC

December 28th 2017

Daniel E. Haggstrom, MD, discusses the developing area of immunotherapy combinations for patients with non-small cell lung cancer.

The Future of Treatment for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: The Changing Landscape of Treatment

December 28th 2017

Enzalutamide in the Context of Nonmetastatic CRPC

December 28th 2017

Darolutamide's Role in Treating Nonmetastatic CRPC

December 28th 2017

MFS: A New Endpoint for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: Considerations for Apalutamide

December 28th 2017

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

December 28th 2017

The Value of AR-Targeted Therapy in CRPC

December 28th 2017

Approaching the Treatment of Nonmetastatic CRPC

December 28th 2017

Understanding Nonmetastatic CRPC: An Overview

December 28th 2017

Treating Advanced Bladder Cancer in the Future

December 28th 2017